News
ACIU
2.420
-1.22%
-0.030
Weekly Report: what happened at ACIU last week (0408-0412)?
Weekly Report · 3d ago
Weekly Report: what happened at ACIU last week (0401-0405)?
Weekly Report · 04/08 11:54
CALM,PLAY and VNDA are among after hour movers
On the Move CALM, PLAY and VNDA are among after hour movers. Sight Sciences (SGHT) and Cal-Maine Foods (CALM) gain. Acorda Therapeutics (ACOR) and Dave & Buster's Entertainment (PLAY) are losers.
Seeking Alpha · 04/02 20:43
Weekly Report: what happened at ACIU last week (0325-0329)?
Weekly Report · 04/01 11:51
Weekly Report: what happened at ACIU last week (0318-0322)?
Weekly Report · 03/25 11:54
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Fulcrum Therapeutics (FULC) and AC Immune SA (ACIU)
TipRanks · 03/19 05:50
Weekly Report: what happened at ACIU last week (0311-0315)?
Weekly Report · 03/18 11:52
AC Immune Price Target Maintained With a $16.00/Share by HC Wainwright & Co.
Dow Jones · 03/15 10:52
HC Wainwright & Co. Reiterates Buy on AC Immune, Maintains $16 Price Target
Benzinga · 03/15 10:41
Buy Rating for AC Immune SA on Promising Alzheimer’s Vaccine Trial Design and Potential Accelerated Approval
TipRanks · 03/15 10:25
ACIU Stock Earnings: AC Immune Beats EPS, Beats Revenue for Q4 2023
AC Immune reported earnings per share of -6 cents. The company reported revenue of $16.69 million. This was 45.91% better than the analyst estimate of $11.44 million. AC Immune also beat out its own estimates for the quarter.
Investorplace · 03/15 02:52
AC Immune files $350M mixed securities shelf
Seeking Alpha · 03/14 20:55
Weekly Report: what happened at ACIU last week (0304-0308)?
Weekly Report · 03/11 11:48
Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP), Elevation Oncology (ELEV) and AC Immune SA (ACIU)
Analysts have issued new ratings on Adaptimmune Therapeutics, Elevation Oncology and AC Immune SA. Leerink Partners analyst Jonathan Chang has reiterated a Hold rating on the Healthcare sector stock. The analysts have also maintained their Buy ratings on the two other stocks.
TipRanks · 03/11 05:00
Weekly Report: what happened at ACIU last week (0226-0301)?
Weekly Report · 03/04 11:51
Catalyst Watch: Jobs report, Powell treks to Congress, Target earnings and major tech conference
Seeking Alpha · 03/01 20:00
Weekly Report: what happened at ACIU last week (0219-0223)?
Weekly Report · 02/26 12:08
AbbVie (ABBV) Announces Appointment of New CEO Robert Michael
NASDAQ · 02/21 15:43
Pfizer's (PFE) Ulcerative Colitis Pill Velsipity Gets EU Nod
NASDAQ · 02/20 12:09
Weekly Report: what happened at ACIU last week (0212-0216)?
Weekly Report · 02/19 12:11
More
Webull provides a variety of real-time ACIU stock news. You can receive the latest news about AC Immune through multiple platforms. This information may help you make smarter investment decisions.
About ACIU
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.